Insmed (NASDAQ:INSM) Receives Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Insmed (NASDAQ:INSM) in a research report report published on Wednesday,Benzinga reports.

A number of other brokerages have also issued reports on INSM. Stifel Nicolaus raised their target price on Insmed from $88.00 to $97.00 and gave the stock a “buy” rating in a research note on Tuesday, February 11th. Wells Fargo & Company raised their price target on shares of Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a research report on Wednesday. JPMorgan Chase & Co. increased their price objective on shares of Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research note on Friday, February 7th. Guggenheim boosted their target price on shares of Insmed from $95.00 to $101.00 and gave the company a “buy” rating in a research report on Friday, February 7th. Finally, Morgan Stanley increased their price target on Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. One investment analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Insmed currently has an average rating of “Moderate Buy” and a consensus price target of $90.86.

Insmed Price Performance

Shares of INSM stock opened at $83.83 on Wednesday. Insmed has a fifty-two week low of $21.92 and a fifty-two week high of $83.89. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The firm has a market capitalization of $15.00 billion, a price-to-earnings ratio of -15.10 and a beta of 1.11. The stock’s 50-day simple moving average is $73.87 and its 200-day simple moving average is $73.45.

Insider Transactions at Insmed

In related news, CFO Sara Bonstein sold 13,302 shares of the business’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $80.00, for a total transaction of $1,064,160.00. Following the completion of the sale, the chief financial officer now directly owns 142,204 shares in the company, valued at approximately $11,376,320. The trade was a 8.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Martina M.D. Flammer sold 37,828 shares of the stock in a transaction on Monday, February 10th. The shares were sold at an average price of $78.61, for a total value of $2,973,659.08. Following the completion of the transaction, the insider now directly owns 100,165 shares of the company’s stock, valued at approximately $7,873,970.65. This represents a 27.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 495,135 shares of company stock valued at $38,409,713 over the last 90 days. Corporate insiders own 4.60% of the company’s stock.

Institutional Trading of Insmed

Several large investors have recently bought and sold shares of INSM. Exchange Traded Concepts LLC boosted its holdings in shares of Insmed by 522.5% during the 3rd quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 627 shares during the last quarter. Creative Planning boosted its stake in Insmed by 31.2% during the third quarter. Creative Planning now owns 44,914 shares of the biopharmaceutical company’s stock worth $3,279,000 after buying an additional 10,668 shares during the last quarter. Blue Trust Inc. grew its holdings in Insmed by 2,348.8% in the 3rd quarter. Blue Trust Inc. now owns 1,959 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 1,879 shares in the last quarter. Allspring Global Investments Holdings LLC increased its stake in shares of Insmed by 18.9% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 390,134 shares of the biopharmaceutical company’s stock worth $28,480,000 after acquiring an additional 62,061 shares during the last quarter. Finally, JCIC Asset Management Inc. purchased a new position in shares of Insmed during the 3rd quarter worth $133,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.